News & Articles

PrecisionPhage has received a €1M investment from Nordic Science Investment, Genetricum, and Unifund. Additionally, PrecisionPhage has secured €1.2M in Deep Tech Accelerator funding from Business Finland, which will be disbursed in three phases based on the company's performance.

This video shows how to do phage genome assembly and analysis with Phagenomics (www.phagenomics.net). All you need are the raw Illumina sequencing data (forward and reverse reads).

The company's CEO, Matti Jalasvuori, emphasizes the importance of courage and the right ecosystem support in driving transformative business. PrecisionPhage specializes in licensing bacteriophages, providing bioinformatics analyses, and developing phage-based solutions for bacterial issues.

PrecisionPhage will be supporting the 7th Targeting Phage Therapy conference in Malta, June 2024.

Among 30 competitors, PrecisionPhage rose to the top and won the Tahko Ski Lift Pitch 2024 competition.

PrecisionPhage participated in the annual AMR conference in beautiful Basel, Switzerland to showcase our phage technologies in the lab and in silico.

PrecisionPhage in talks with Finnish ambassador and delegates in the USA about phage technology.

PrecisionPhage participated in a venture capital event in Jyväskylä arranged by Startup Factory.

We partook in the Business Networking Day organised by the University of Jyväskylä to talk about all things phage.

We presented our phage endeavour to a panel of nanoscience experts.

We rallied up our phage forces and pitched at the Business Rally Investor Day.

PrecisionPhage visits the Virus club in the University of Helsinki to discuss phages.

PrecisionPhage made a visit to the University of Turku to talk about phages and our company.

We met with UK government representatives to discuss phages and deep tech.

PrecisionPhage participated in the annual WeNSC meeting in Konnevesi, Finland.

PrecisionPhage and the future of phage therapy was covered by Kauppalehti (Picture: Petteri Kivimäki, Kauppalehti).